A vectored measles virus induces hepatitis B surface antigen antibodies while protecting macaques against measles virus challenge.
about
Biosafety considerations for attenuated measles virus vectors used in virotherapy and vaccinationReplicon RNA Viral Vectors as VaccinesA Highly Immunogenic and Protective Middle East Respiratory Syndrome Coronavirus Vaccine Based on a Recombinant Measles Virus Vaccine Platform.Measles virus entry through the signaling lymphocyte activation molecule governs efficacy of mantle cell lymphoma radiovirotherapy.Nuclear reprogramming with a non-integrating human RNA virus.New vaccine design based on defective genomes that combines features of attenuated and inactivated vaccinesMeasles virus selectively blind to signaling lymphocytic activation molecule (SLAM; CD150) is attenuated and induces strong adaptive immune responses in rhesus monkeys.Pan-viral specificity of IFN-induced genes reveals new roles for cGAS in innate immunityA recombinant measles virus unable to antagonize STAT1 function cannot control inflammation and is attenuated in rhesus monkeys.Immunogenicity of attenuated measles virus engineered to express Helicobacter pylori neutrophil-activating protein.Live-attenuated measles virus vaccine targets dendritic cells and macrophages in muscle of nonhuman primates.In vivo ligands of MDA5 and RIG-I in measles virus-infected cells.Envelope-chimeric entry-targeted measles virus escapes neutralization and achieves oncolysis.Measles Virus Defective Interfering RNAs Are Generated Frequently and Early in the Absence of C Protein and Can Be Destabilized by Adenosine Deaminase Acting on RNA-1-Like Hypermutations.An immune competent mouse model for the characterization of recombinant measles vaccines.Multicenter Safety and Immunogenicity Trial of an Attenuated Measles Vaccine for NHP.Broadly neutralizing immune responses against hepatitis C virus induced by vectored measles viruses and a recombinant envelope protein boosterATP hydrolysis by the viral RNA sensor RIG-I prevents unintentional recognition of self-RNA.Attenuation of V- or C-defective measles viruses: infection control by the inflammatory and interferon responses of rhesus monkeys.Measles virus blind to its epithelial cell receptor remains virulent in rhesus monkeys but cannot cross the airway epithelium and is not shed.Generation of a More Immunogenic Measles Vaccine by Increasing Its Hemagglutinin Expression.The successful induction of T-cell and antibody responses by a recombinant measles virus-vectored tetravalent dengue vaccine provides partial protection against dengue-2 infection.Measles vaccination: new strategies and formulations.Protective anti-hepatitis B virus responses in rhesus monkeys primed with a vectored measles virus and boosted with a single dose of hepatitis B surface antigen.Sequence and immunogenicity of a clinically approved novel measles virus vaccine vector.Measles virus expressed Helicobacter pylori neutrophil-activating protein significantly enhances the immunogenicity of poor immunogens.Measles virus C protein impairs production of defective copyback double-stranded viral RNA and activation of protein kinase R.Reverse genetics of Mononegavirales: How they work, new vaccines, and new cancer therapeuticsVaccine platform recombinant measles virus.Novel viral vectors in infectious diseases.Immunogenic Subviral Particles Displaying Domain III of Dengue 2 Envelope Protein Vectored by Measles Virus.Development of Recombinant Measles Virus-Based Vaccines.Antigenic Drift Defines a New D4 Subgenotype of Measles Virus.Cell tropism and pathogenesis of measles virus in monkeys.Evaluation of Measles Vaccine Virus as a Vector to Deliver Respiratory Syncytial Virus Fusion Protein or Epstein-Barr Virus Glycoprotein gp350.Relevance of a pre-existing measles immunity prior immunization with a recombinant measles virus vector.Development of measles virus-based shielded oncolytic vectors: suitability of other paramyxovirus glycoproteins.Diverse Viruses Require the Calcium Transporter SPCA1 for Maturation and Spread.A Recombinant Measles Vaccine with Enhanced Resistance to Passive Immunity.Antigen-specific oncolytic MV-based tumor vaccines through presentation of selected tumor-associated antigens on infected cells or virus-like particles.
P2860
Q26700080-48169D98-F201-42BB-8EFF-FCF7ECFB5A8CQ28076639-4E407B2C-8C9F-49B8-945B-0CD557526340Q30378994-22FD494D-A8A3-41E2-B12C-CAAB2CA1038EQ30557338-00F9AC76-3F9A-4BBC-A1CE-94EC57DF0FA2Q30645806-1BEE2DB8-9FA1-4963-ABF1-6ED4F54FD028Q33573531-00C37F8D-2E92-4A7C-9ED3-8F035F110FF5Q33725565-804D6D6A-2567-4162-9EB8-EBEF7FD82FD6Q33830730-C4269F7C-B026-44CC-8875-5AE2F6EE1578Q34457823-92E933E8-8042-40D9-ABD5-FB3652AB6DFDQ35096934-4B850AAC-29D6-4423-AC7F-9C8AFE0C6751Q35115588-F642E0BC-02AB-4A72-A1D4-24FE433304EFQ35152238-EFF5439A-37AA-4887-A2ED-0AA738931863Q35285887-BF950B34-5B80-493D-98C4-12FEF7A062F9Q35861183-4653EB0B-2E98-48DD-B32F-F750967415B9Q35887095-2BB48CA0-58FC-497C-B1D1-D365847CA073Q36197585-158F9BC7-B7E5-4875-893B-6A90FB47DFBCQ36363203-2BDBF755-1957-4A30-8061-311705CCA356Q36520858-54982327-6D0D-44EC-A477-E544EDAC9DEBQ36673332-791175F2-1B39-4FC4-A9E5-DA816FFD25AAQ36726124-E67667A0-1DEF-4771-BAF5-694FC9E05D2FQ37069798-04D488C7-3848-4F26-A7BC-50DF051E9A10Q37135489-53E3CC44-A26C-4187-B48F-08BDFB98A3DBQ37290110-8BCD7E0E-44AA-4F4D-BF64-C7517CC32004Q37333844-110E2005-802B-42D1-B777-A5535B3A7391Q37478331-795A9C7B-970A-42FF-A151-D595A2CE917FQ37520259-78EB7B50-A2D9-4AFD-B721-FE87A6F29022Q37547798-EC29E1DA-71B1-4572-92DB-8C9F891BB5C9Q38363535-ACEE3BE2-7156-4C0F-BA8E-B3D7E55C20ECQ38657271-6D1F65A9-6DC5-43F1-A9D5-32A5F0A9A5E8Q40059020-37AF9CAC-3D3B-4513-B3BA-5D2098734489Q40140203-D1ACB646-A169-4904-9226-4A8847BA515EQ40259612-DB3DB0F1-59DC-4DE4-ACCC-A8103A313039Q40267862-C733314D-A7A4-4CC0-8104-09CB11C2D8CEQ41023141-25AC7DF2-E5E3-4475-BA5C-292FFB2CD29EQ41557807-317D87A2-DB3B-449B-967B-C43DEB1DEC7EQ41871491-EC537308-5EFB-486E-8415-64F46371280FQ41890251-E94BDDB4-DE92-4E94-AF83-88B61A8F35EDQ41918000-347F1FB6-2B0B-4531-B3ED-8B9FBDD28CB0Q41933011-E3602031-AD1C-4EAA-A5A9-BCCC8AD79C25Q45323818-86EDE70C-7978-4642-AB12-FB88C8212385
P2860
A vectored measles virus induces hepatitis B surface antigen antibodies while protecting macaques against measles virus challenge.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
A vectored measles virus induc ...... ainst measles virus challenge.
@ast
A vectored measles virus induc ...... ainst measles virus challenge.
@en
type
label
A vectored measles virus induc ...... ainst measles virus challenge.
@ast
A vectored measles virus induc ...... ainst measles virus challenge.
@en
prefLabel
A vectored measles virus induc ...... ainst measles virus challenge.
@ast
A vectored measles virus induc ...... ainst measles virus challenge.
@en
P2093
P2860
P921
P356
P1433
P1476
A vectored measles virus induc ...... ainst measles virus challenge.
@en
P2093
Gregory Hodge
Jorge Reyes del Valle
Michael B McChesney
Nicholas J Wegner
Patricia Devaux
P2860
P304
10597-10605
P356
10.1128/JVI.00923-07
P407
P577
2007-07-18T00:00:00Z